We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
1-Year Est. Return
524.64%
This Fund
S&P 500
This Quarter
Est. Return
+33.44%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$962M
AUM Growth
-$17.7M
(-1.8%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-10.94%
Top 10 Holdings %
Top 10 Hldgs %
42.32%
Holding
98
New
25
Increased
18
Reduced
27
Closed
25
Avg Time Held Equity + Options
4
quarters
Top 10 Avg Time Held Equity + Options
1
quarter
Top 20 Avg Time Held Equity + Options
2.3
quarters
Avg Time Held Equity only
4.4
quarters
Top 10 Avg Time Held Equity only
1
quarter
Top 20 Avg Time Held Equity only
2.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$20.8M |
| 2 |
Sagimet Biosciences
SGMT
|
+$19.9M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$19.1M |
| 4 |
Celcuity
CELC
|
+$16.5M |
| 5 |
Oruka Therapeutics
ORKA
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KalVista Pharmaceuticals
KALV
|
+$57.9M |
| 2 |
Nuvalent
NUVL
|
+$36.4M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$23.1M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$18.5M |
| 5 |
Kodiak Sciences
KOD
|
+$17.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.68% |
| 2 | Miscellaneous | 6.61% |
| 3 | Financials | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Ascendis Pharma A/S
ASND
$14.7B
| $55M | 5.72% |
206,234
+81,576
| +65% | +$19.1M |
2024 Q3
7 quarters
|
|
|
2
Celcuity
CELC
$3.09B
| $52.4M | 5.45% |
500,996
+143,093
| +40% | +$16.5M |
2025 Q3
3 quarters
|
|
3
Cogent Biosciences
COGT
$4.87B
| $49.6M | 5.15% |
1,280,707
-33,482
| -3% | -$1.17M |
2025 Q3
3 quarters
|
|
4
UroGen Pharma
URGN
$1.87B
| $47.9M | 4.98% |
1,301,979
-201,066
| -13% | -$5.45M |
2023 Q3
11 quarters
|
|
5
Immunome
IMNM
$2.07B
| $42.7M | 4.44% |
2,017,009
+166,731
| +9% | +$3.57M |
2025 Q4
2 quarters
|
|
|
6
Dianthus Therapeutics
DNTH
$4.34B
| $38M | 3.95% |
390,000
-264,746
| -40% | -$23.1M |
2025 Q1
5 quarters
|
|
7
Rhythm Pharmaceuticals
RYTM
$5.96B
| $34.6M | 3.59% |
311,461
+5,461
| +2% | +$494K |
2023 Q2
12 quarters
|
|
|
8
Oruka Therapeutics
ORKA
$5.18B
| $33.6M | 3.49% |
352,802
+201,894
| +134% | +$13.5M |
2026 Q1
1 quarter
|
|
9
Monte Rosa Therapeutics
GLUE
$844M
| $26.8M | 2.79% |
1,108,295
-893,745
| -45% | -$16.9M |
2025 Q3
3 quarters
|
|
10
Syndax Pharmaceuticals
SNDX
$1.25B
| $26.5M | 2.76% |
1,214,390
+325,403
| +37% | +$6.77M |
2024 Q2
8 quarters
|
|
|
11
Enliven Therapeutics
ELVN
$2.89B
| $24.8M | 2.58% |
+489,382
| New | +$20.8M |
2026 Q2
0 quarters
|
|
12
Immunovant
IMVT
$5.93B
| $23.9M | 2.48% |
619,096
+204,860
| +49% | +$6.24M |
2026 Q1
1 quarter
|
|
13
Erasca
ERAS
$5.17B
| $23.1M | 2.4% |
1,263,026
-588,786
| -32% | -$8.42M |
2024 Q1
9 quarters
|
|
|
14
Sagimet Biosciences
SGMT
$566M
| $22.6M | 2.35% |
+2,927,698
| New | +$19.9M |
2026 Q2
0 quarters
|
|
15
Abivax
ABVX
$7.52B
| $22.6M | 2.35% |
169,593
-132,937
| -44% | -$15M |
2025 Q3
3 quarters
|
|
16
Praxis Precision Medicines
PRAX
$6.79B
| $22M | 2.29% |
65,679
-5,873
| -8% | -$1.86M |
2023 Q2
12 quarters
|
|
|
17
Kodiak Sciences
KOD
$5.76B
| $21.3M | 2.21% |
546,256
-445,674
| -45% | -$17.3M |
2023 Q3
11 quarters
|
|
18
PUT
ARK Genomic Revolution ETF
ARKG
$2.06B
| $21M | 2.19% |
+500,000
| New | +$15.9M |
2026 Q2
0 quarters
|
|
19
Definium Therapeutics
DFTX
$4.62B
| $18.8M | 1.96% |
+400,000
| New | +$9.88M |
2026 Q2
0 quarters
|
|
20
Veracyte
VCYT
$3.47B
| $18.7M | 1.94% |
318,001
+138,301
| +77% | +$5.8M |
2021 Q1
21 quarters
|
|
|
21
CALL
Syndax Pharmaceuticals
SNDX
$1.25B
| $15.2M | 1.58% |
693,600
+373,600
| +117% | +$7.77M |
2026 Q1
1 quarter
|
|
22
Guardant Health
GH
$21.8B
| $15M | 1.56% |
99,826
+1,312
| +1% | +$143K |
2025 Q4
2 quarters
|
|
23
C4 Therapeutics
CCCC
$342M
| $14.2M | 1.47% |
3,032,060
+1,120,275
| +59% | +$3.83M |
2025 Q3
3 quarters
|
|
24
Zenas BioPharma
ZBIO
$1.64B
| $12.9M | 1.34% |
509,789
-626,146
| -55% | -$12.4M |
2026 Q1
1 quarter
|
|
25
Trevi Therapeutics
TRVI
$1.75B
| $12.6M | 1.31% |
678,095
+166,968
| +33% | +$2.43M |
2022 Q3
15 quarters
|
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
BEAM
RAM
Silverarc Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Silverarc Capital Management held 98 positions worth $962M, down 1.8% from $980M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Silverarc Capital Management withdrew a net $105M in Q2 2026, closing 25 positions and reducing 27 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $57.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Silverarc Capital Management opened a new position in Enliven Therapeutics worth $24.8M.
- Silverarc Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 489,382 shares worth $24.8M.
- Silverarc Capital Management added most to Ascendis Pharma A/S in Q2 2026, an estimated $19.1M increase.
- Silverarc Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $23.1M.
- Silverarc Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $57.9M.
- Silverarc Capital Management's ten largest holdings make up 42% of its $962M portfolio in Q2 2026.
- Silverarc Capital Management opened 25 new positions and closed 25 in Q2 2026.
- Silverarc Capital Management's portfolio value fell 1.8% quarter-over-quarter to $962M.
Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.